Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,010 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators. Kizaki M, et al. Among authors: takahashi n. Int J Hematol. 2019 Apr;109(4):426-439. doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb 14. Int J Hematol. 2019. PMID: 30762219 Clinical Trial.
Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
Takahashi N, Miura I, Kobayashi Y, Kume M, Yoshioka T, Otane W, Ohtsubo K, Takahashi K, Kitabayashi A, Kawabata Y, Hirokawa M, Nishijima H, Ichinohasama R, Decoteau J, Miura AB, Sawada K. Takahashi N, et al. Among authors: takahashi k. Int J Hematol. 2005 Apr;81(3):235-41. doi: 10.1532/IJH97.04095. Int J Hematol. 2005. PMID: 15814334 Clinical Trial.
Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study.
Tamai H, Yamaguchi H, Hamaguchi H, Yagasaki F, Bessho M, Kobayashi T, Akiyama H, Sakamaki H, Takahashi S, Tojo A, Ohmine K, Ozawa K, Okumura H, Nakao S, Arai A, Miura O, Toyota S, Gomi S, Murai Y, Usui N, Miyazawa K, Ohyashiki K, Takahashi N, Sawada K, Kato A, Oshimi K, Inokuchi K, Dan K. Tamai H, et al. Among authors: takahashi n, takahashi s. Int J Hematol. 2008 Mar;87(2):195-202. doi: 10.1007/s12185-008-0034-2. Epub 2008 Feb 6. Int J Hematol. 2008. PMID: 18253706
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Saglio G, et al. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525993 Free article. Clinical Trial.
Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia.
Takahashi N, Wakita H, Miura M, Scott SA, Nishii K, Masuko M, Sakai M, Maeda Y, Ishige K, Kashimura M, Fujikawa K, Fukazawa M, Katayama T, Monma F, Narita M, Urase F, Furukawa T, Miyazaki Y, Katayama N, Sawada K. Takahashi N, et al. Clin Pharmacol Ther. 2010 Dec;88(6):809-13. doi: 10.1038/clpt.2010.186. Epub 2010 Oct 27. Clin Pharmacol Ther. 2010. PMID: 20980997
Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma.
Nagai H, Ogura M, Kusumoto S, Takahashi N, Yamaguchi M, Takayama N, Kinoshita T, Motoji T, Ohyashiki K, Kosugi H, Matsuda S, Ohnishi K, Omachi K, Hotta T. Nagai H, et al. Among authors: takahashi n. Eur J Haematol. 2011 Feb;86(2):117-23. doi: 10.1111/j.1600-0609.2010.01552.x. Epub 2010 Dec 29. Eur J Haematol. 2011. PMID: 21070370 Clinical Trial.
6,010 results